Modulation of UDP-glucuronosyltransferase activity by endogenous compounds

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 2, 2010, Pages 134-148

  Ishii, Yuji ^a   Nurrochmad, Arief ^b   Yamada, Hideyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

Activator; Adenine; ATP; Fatty acid; Fatty acyl CoA; Inhibitor; NAD; NADP; UDP glucuronosyltransferase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACYL COENZYME A; ADENINE; ADENINE NUCLEOTIDE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CYTIDINE TRIPHOSPHATE; CYTOCHROME P450 3A4; ESTROGEN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; INTERLEUKIN 1ALPHA; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TESTOSTERONE; THYROID HORMONE; UNINDEXED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; URSODEOXYCHOLIC ACID; ZIDOVUDINE;

ANALGESIC ACTIVITY; CANCER PAIN; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; LIVER MICROSOME; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77952662988     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.134     Document Type: Review

References (147)

1. Guengerich, F. P.: Characterization of human microsomal cytochrome P-450 enzymes. Annu. Rev. Pharmacol. Toxicol., 29: 241-264 (1989).
2. Oguri, K., Yamada, H. and Yoshimura, H.: Regiochemistry of cytochrome P450 isozymes. Annu. Rev. Pharmacol. Toxicol., 34: 251-279 (1994).
3. Tukey, R. H. and Strassburg, C. P.: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol., 40: 581-616 (2000).
4. Miners, J. O., Smith, P. A., Sorich, M. J., McKinnon, R. A. and Mackenzie, P. I.: Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu. Rev. Pharmacol. Toxicol., 44: 1-25 (2004).
5. Tephly, T. R. and Burchell, B.: UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends Pharmacol. Sci., 11: 276-279 (1990).
6. Meech, R. and Mackenzie, P. I.: Structure and function of uridine diphosphate glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol., 24: 907-915 (1997).
7. Mackenzie, P. I., Owen, I. S., Burchell, B., Bock, K. W., Bairoch, A., Beálanger, A., Fournel-Gigleux, S., Green, M., Hum, D.W., Iyanagi, T., Lancet, D., Louisot, P., Magdalou, J., Roy-Chowdhury, J., Ritter, J. K., Schachter, H., Tephly, T. R., Tipton, K. F. and Nebert, D. W.: The UDP-glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7: 255-269 (1997).
8. Ritter, J. K.: Roles of glucuronidation and UDPglucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact., 129: 171-193 (2000).
9. Mackenzie, P. I., Bock, K. W., Burchell B., Guillemette, C., Ikushiro, S., Iyanagi, T., Miners, J. O., Owens, I. S. and Nebert, D. W.: Nomenclature update for the mammalian UDPglycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics, 15: 677-685 (2005).
10. Iyanagi, T.: Molecular mechanism of phase I and phase II drugmetabolizing enzymes: implications for detoxification. Int. Rev. Cytol., 260: 35-112 (2007).
11. Shimomura, K., Kamata, O., Ueki, S., Ida, S., Oguri, K., Yoshimura, H. and Tsukamoto, H.: Analgesic effect of morphine glucuronides. Tohoku J. Exp. Med., 105: 45-52 (1971).
12. Formelli, F., Barua, A. B. and Olson, J. A.: Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl b-glucuronide. FASEB J., 10: 1014-1024 (1996).
13. Mackenzie, P. I., Rogers, A., Treloar, J., Jorgensen, B. R., Miners, J. O. and Meech, R.: Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. J. Biol. Chem., 283: 36205-36210 (2008).
14. Burchell, B.: Genetic variation of human UDPglucuronosyltransferase: implications in disease and drug glucuronidation. Am. J. Pharmacogenomics, 3: 37-52 (2003).
15. Mackenzie, P. I., Gregory, P. A., Gardner-Stephen, D. A., Lewinsky, R. H., Jorgensen, B. R., Nishiyama, T., Xie, W. and Radominska-Pandya, A.: Regulation of UDP-glucuronosyltransferase genes. Curr. Drug Metab., 4: 249-257 (2003).
16. Guillemette, C.: Pharmacogenomics of human UDPglucuronosyltransferase enzymes. Pharmacogenomics J., 3: 136-158 (2003).
17. Shepherd, S. R., Baird, S. J., Hallinan, T. and Burchell, B.: An investigation of the transverse topology of bilirubin UDPglucuronosyltransferase in rat hepatic endoplasmic reticulum. Biochem. J., 259: 617-620 (1989).
18. Radominska-Pandya, A., Ouzzine, M., Fournel-Gigleux, S. and Magdalou, J.: Structure of UDP-glucuronosyltransferases in membranes. Methods Enzymol., 400: 116-147 (2005).
19. Winsnes, A.: Studies on the activation in vitro of glucuronyltransferase. Biochim. Biophys. Acta, 191: 279-291 (1969).
20. Hauser, S. C., Ziurys, J. C. and Gollan, J. L.: A membrane transporter mediates access of uridine 5′-diphosphoglucuronic acid from the cytosol into the endoplasmic reticulum of rat hepatocytes: implications for glucuronidation reactions. Biochim. Biophys. Acta, 967: 149-157 (1988).
21. Muraoka, M., Kawakita, M. and Ishida, N.: Molecular characterization of human UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter, a novel nucleotide sugar transporter with dual substrate specificity. FEBS Lett., 495: 87-93 (2001).
22. Muraoka, M., Miki, T., Ishida, N., Hara, T. and Kawakita, M.: Variety of nucleotide sugar transporters with respect to the interaction with nucleoside monoand diphosphates. J. Biol. Chem., 282: 24615-24622 (2007).
23. Keppler, D., Leier, I. and Jedlitschky, G.: Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem., 378: 787-791 (1997).
24. Hirohashi, T., Suzuki, H. and Sugiyama, Y.: Characterization of the transport properties of cloned rat multidrug resistanceassociated protein 3 (MRP3). J. Biol. Chem., 274: 15181-15185 (1999).
25. Cui, Y., Koä nig, J., Leier, I., Buchholz, U. and Keppler, D.: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem., 276: 9626-9630 (2001).
26. Cattori, V., Hagenbuch, B., Hagenbuch, N., Stieger, B., Ha, R., Winterhalter, K. E. and Meier, P. J.: Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. FEBS Lett., 474: 242-245 (2000).
27. Konig, J., Cui, Y., Nies, A. T. and Keppler, D.: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem., 275: 23161-23168 (2000).
28. Evans, W. E. and Relling, M. V.: Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286: 487-491 (1999).
29. Ishii, Y., Hansen, A. J., Mackenzie, P. I.: Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol. Pharmacol., 57: 940-947 (2000).
30. Gregory, P. A., Gardner-Stephen, D. A., Lewinsky, R. H., Duncliffe, K. N. and Mackenzie, P. I.: Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential regulation through an interior-like region. J. Biol. Chem., 278: 36107-36114 (2003).
31. Barbier, O., Villeneuve, L., Bocher, V., Fontaine, C., Torra, I.P., Duhem, C., Kosykh, V., Fruchart, J.C., Guillemette, C. and Staels, B.: The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J. Biol. Chem., 278: 13975-13983 (2003).
32. Gardner-Stephen, D. A. and Mackenzie, P. I.: Hepatocyte nuclear factor1 transcription factors are essential for the UDPglucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha. Pharmacogenet Genomics, 17: 25-36 (2007).
33. Aueviriyavit, S., Furihata, T., Morimoto, K., Kobayashi, K. and Chiba, K.: Hepatocyte nuclear factor 1 alpha and 4 alpha are factors involved in interindividual variability in the expression of UGT1A6 and UGT1A9 but not UGT1A1, UGT1A3 and UGT1A4 mRNA in human livers. Drug Metab. Pharmacokinet., 22: 391-398 (2007).
34. Basu, N. K., Kovarova, M., Garza, A., Kubota, S., Saha, T., Mitra, P. S., Banerjee, R., Rivera, J. and Owens, I. S.: Phosphorylation of a UDP-glucuronosyltransferase regulates substrate specificity. Proc. Natl. Acad. Sci. U.S.A., 102: 6285-6290 (2005).
35. Basu, N. K., Kole, L., Basu, M., Chakraborty, K., Mitra, P. S. and Owens, I. S.: The major chemical-detoxifying system of UDP-glucuronosyltransferases requires regulated phosphorylation supported by protein kinase C. J. Biol. Chem., 283: 23048-23061 (2007).
36. Barbier, O., Girard, C., Breton, R., Belanger, A. and Hum, D. W.: N-Glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes. Biochemistry, 39: 11540-11552 (2000).
37. Ikushiro, S., Emi, Y. and Iyanagi, T.: Protein-protein interactions between UDP-glucuronosyltransferase isozymes in rat hepatic microsomes. Biochemistry, 36: 7154-7161 (1997).
38. Meech, R. and Mackenzie, P. I.: UDP-glucuronosyltransferase, the role of the amino terminus in dimerization. J. Biol. Chem., 272: 26913-26917 (1997).
39. Ghosh, S. S., Sappal, B. S., Kalpana, G. V., Lee, S. W., Roy Chowdhury, J. and Roy Chowdhury, N.: Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications. J. Biol. Chem., 276: 42108-42115 (2001).
40. Ishii, Y., Miyoshi, A., Watanabe, R., Tsuruda, K., Tsuda, M., Yamaguchi-Nagamatsu, Y., Yoshisue, K., Tanaka, M., Maji, D., Ohgiya, S. and Oguri, K.: Simultaneous expression of guinea pig UDP-glucuronosyltransferase 2B21 and 2B22 in COS-7 cells enhances UDP-glucuronosyltransferase 2B21-catalyzed morphine-6-glucuronide formation. Mol. Pharmacol., 60: 1040-1048 (2001).
41. Kurkela, M., Garcia-Horsman, J. A., Luukkanen, L., Morsky, S., Taskinen, J., Baumann, M., Kostiainen, R., Hirvonen, J. and Finel, M.: Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J. Biol. Chem., 278: 3536-3544 (2003).
42. Ishii, Y., Miyoshi, A., Maji, D., Yamada, H. and Oguri, K.: Simultaneous expression of guinea pig UDP-glucuronosyltransferase 2B21 and 2B22 in COS-7 cells enhances UDPglucuronosyltransferase 2B21-catalyzed chloramphenicol glucuronidation. Drug Metab. Dispos., 32: 1057-1060 (2004).
43. Operanãa, T. N. and Tukey, R. H.: Oligomerization of the UDPglucuronosyltransferase 1A proteins: homoand heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation, J. Biol. Chem., 282: 4821-4829 (2007).
44. Fujiwara, R., Nakajima, M., Yamanaka, H., Nakamura, A., Katoh, M., Ikushiro, S., Sakaki, T. and Yokoi, T.: Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab. Dispos., 35: 747-757 (2007).
45. Girard, H., Leávesque, E., Bellemare, J., Journault, K., Caillier, B. and Guillemette, C.: Genetic diversity at the UGT1 locus is amplified by a novel 3′ alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet. Genomics, 17: 1077-1089 (2007).
46. Taura, K., Yamada, H., Hagino, Y., Ishii, Y., Mori, M. and Oguri, K.: Interaction between cytochrome P450 and other drug-metabolizing enzymes: evidence for an association of CYP1A1 with microsomal epoxide hydrolase and UDPglucuronosyltransferase. Biochem. Biophys. Res. Commun., 273: 1048-1052 (2000).
47. Fremont, J. J., Wang, R. W. and King, C. D.: Co-immunoprecipitation of UDP-glucuronosyltransferase (UGT) isoforms and cytochrome P450 3A4. Mol. Pharmacol., 67: 260-262 (2005).
48. Takeda, S., Ishii, Y., Iwanaga, M., Mackenzie, P. I., Nagata, K., Yamazoe, Y., Oguri, K. and Yamada, H.: Modulation of UDPglucuronosyltransferase function by cytochrome P450: evi dence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol. Pharmacol., 67: 665-672 (2005).
49. Takeda, S., Ishii, Y., Mackenzie, P. I., Nagata, K., Yamazoe, Y., Oguri, K. and Yamada, H.: Modulation of UDPglucuronosyltransferase 2B7 function by cytochrome P450s in vitro: Differential effects of CYP1A2, CYP2C9 and CYP3A4, Biol. Pharm. Bull., 28: 2026-2027 (2005).
50. Takeda, S., Ishii, Y., Iwanaga, M., Nurrochmad A, Ito Y, Mackenzie, P. I., Nagata, K., Yamazoe, Y., Oguri, K. and Yamada, H.: Interaction of cytochrome P450 3A4 and UDPglucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction. Mol. Pharmacol., 75: 956-964 (2009).
51. Ishii, Y., Iwanaga, M., Nishimura, Y., Takeda, S., Ikushiro, S., Nagata, K., Yamazoe, Y., Mackenzie, P. I. and Yamada, H.: Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex. Drug Metab. Pharmacokinet., 22: 367-376 (2007).
52. Gardner-Stephen, D. A. and Mackenzie, P. I.: Liver-enriched transcription factors and their role in regulating UDP glucuronosyltransferase gene expression. Curr. Drug Metab., 9: 439-452 (2008).
53. Mackenzie, P. I., Hu, D. G. and Gardner-Stephen, D. A.: The regulation of UDP-glucuronoyltransferase genes by tissuespecific and ligand-activated transcription factors. Drug Metab. Rev., 42: 95-105 (2010).
54. Ishii, Y., Takeda, S., Yamada, H. and Oguri, K.: Functional protein-protein interaction of drug metabolizing enzymes. Front. Biosci., 10: 887-895 (2005).
55. Ishii, Y., Takeda, S. and Yamada, H.: Modulation of UDPglucuronosyltransferase activity by protein-protein association. Drug Metab. Rev., 42: 145-158 (2010).
56. Kiang, T. K. L., Ensom, M. H. H. and Chang, T. K. H.: UDPglucuronosyltransferases and drug-drug interactions. Pharmacol. Ther., 106: 97-132 (2005).
57. Yokota, H., Ando, F., Iwano, H. and Yuasa, A.: Inhibitory effects of uridine diphosphate on UDP-glucuronosyltransferase. Life Sci., 63: 1693-1699 (1998).
58. Fujiwara, R., Nakajima, M., Yamanaka, H., Katoh, M. and Yokoi, T.: Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Drug Metab. Dispos., 36: 361-367 (2008).
59. Nishimura, Y., Maeda, S., Ikushiro, S., Mackenzie, P. I., Ishii, Y. and Yamada, H.: Inhibitory effects of adenine nucleotides and related substances on UDP-glucuronosyltransferase: structure-effect relationships and evidence for an allosteric mechanism. Biochim. Biophys. Acta, 1770: 1557-1566 (2007).
60. Koster, A. S. and Noordhoek, J.: Kinetic properties of the rat intestinal microsomal 1-naphthol: UDP-glucuronosyl transferase. Inhibition by UDP and UDP-N-acetylglucosamine. Biochim. Biophys. Acta, 761: 76-85 (1983).
61. Leávesque, E., Beaulieu, M., Guillemette, C., Hum, D. W. and Beálanger, A.: Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology, 139: 2375-2381 (1998).
62. Carter, D. B., Deibel, M. R. Jr, Dunn, C. J., Tomich, C. S., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., Harris, P. K. W., Yem, A. W., Waszak, G. A., Chosay, J. G., Sieu, L. C., Hardee, M. M., Zurcher-Neely, H. A., Reardon, I. M., Heinrikson, R. L., Truesdell, S. E., Shelly, J. A., Eessalu, T. E., Taylor, B. M. and Tracey, D. E.: Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature, 344: 633-638 (1990).
63. Leávesque, E., Beaulieu, M., Guillemette, C., Hum, D. W. and Beálanger, A.: Effect of fibroblastic growth factors (FGF) on steroid UDP-glucuronosyltransferase expression and activity in the LNCaP cell line. J. Steroid. Biochem. Mol. Biol., 64: 43-48 (1998).
64. Rao, G. S., Haueter, G., Rao, M. L. and Breuer, H.: Steroid glucuronyltransferases of rat liver. Properties of oestrone and testosterone glucuronyltransferases and the effect of ovariectomy, castration and administration of steroids on the enzymes. Biochem. J., 162: 545-556 (1977).
65. Watanabe, H. K. and Matsui, M.: Effects of steroid hormones and xenobiotics on the pubertal development of UDPglucuronosyltransferase activities towards androsterone and 4-nitrophenol in Wistar rats. Biochem. J., 222: 321-326 (1984).
66. Zhu, B. T., Suchar, L. A., Huang, M. T. and Conney, A. H.: Similarities and differences in the glucuronidation of estradiol and estrone by UDP-glucuronosyltransferase in liver microsomes from male and female rats. Biochem. Pharmacol., 51: 1195-1202 (1996).
67. Herber, R., Magdalou, J., Haumont, M., Bidault, R., van Es, H. and Siest, G.: Glucuronidation of 3′-azido-3′-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones. Biochim. Biophys. Acta, 1139: 20-24 (1992).
68. Goudonnet, H., Magdalou, J., Mounie, J., Naoumi, A., Viriot, M. L., Escousse, A., Siest, G. and Truchot, R.: Differential action of thyroid hormones and chemically related compounds on the activity of UDP-glucuronosyltransferases and cytochrome P-450 isozymes in rat liver. Biochim. Biophys. Acta, 1035: 12-19 (1990).
69. Sáanchez Pozzi, E. J., Luquita, M. G., Catania, V. A., Rodráfguez Garay, E. A. and Mottino, A. D.: Inhibition of rat liver microsomal bilirubin UDP-glucuronosyltransferase by ursodeoxycholic acid. Life Sci., 55: 111-120 (1994).
70. Galan, A. I., Jimenez, R., Munã oz, M. E. and Gonzalez, J.: Effects of ursodeoxycholate on maximal biliary secretion of bilirubin in the rat. Biochem. Pharmacol., 39: 1175-1180 (1990).
71. Csala, M., Bánhegyi, G., Kardon, T., Fulceri, R., Gamberucci, A., Giunti, R., Benedetti, A. and Mandl, J.: Inhibition of glucuronidation by an acyl-CoA-mediated indirect mechanism. Biochem. Pharmacol., 52: 1127-1131 (1996).
72. Yamashita, A., Nagatsuka, T., Watanabe, M., Kondo, H., Sugiura, T. and Waku, K.: Inhibition of UDP-glucuronosyltransferase activity by fatty acyl-CoA. Kinetic studies and structureactivity relationship. Biochem. Pharmacol., 53: 561-570 (1997).
73. Okamura, K., Ishii, Y., Ikushiro, S., Mackenzie, P. I., and Yamada, H.: Fatty acyl-CoA as an endogenous activator of UDP-glucuronosyltransferases. Biochem. Biophys. Res. Commun., 345: 1649-1656 (2006).
74. Krcmery, M. and Zakim, D.: Effects of oleoyl-CoA on the activity and functional state of UDP-glucuronosyltransferase. Biochem. Pharmacol., 46: 897-904 (1993).
75. Yamashita, A., Watanabe, M., Tonegawa, T., Sugiura, T. and Waku, K.: Acyl-CoA binding and acylation of UDPglucuronosyltransferase isoforms of rat liver: their effect on enzyme activity. Biochem. J., 312: 301-308 (1995).
76. Odermatt, A., Arnold, P., Stauffer, A., Frey, B. M. and Frey, F. J.: The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J. Biol. Chem., 274: 28762-28770 (1999).
77. Ohno, S., Payne, H. W., Morrison, M. and Beutler, E.: Hexose-6-phosphate dehydrogenase found in human liver. Science, 153: 1015-1016 (1966).
78. Hino, Y. and Minakami, S.: Hexose-6-phosphate and 6-phosphogluconate dehydrogenases of rat liver microsomes. Involvement in NADPH and carbon dioxide generation in the luminal space of microsomal vesicles. J. Biochem. (Tokyo), 92: 547-557 (1982).
79. Dorner, A. J. and Kaufman, R. J.: The levels of endoplasmic reticulum proteins and ATP affect folding and secretion of selective proteins. Biologicals, 22: 103-112 (1994).
80. Hallinan, T., Pohl, K. R. and de Brito, R.: Studies on the inhibition of hepatic microsomal glucuronidation by uridine nucleotides or adenosine triphosphate. Med. Biol., 57: 269-273 (1979).
81. Yan, Z. and Caldwell, G. W.: Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDPglycosyltransferases. Eur. J. Drug Metab. Pharmacokinet., 28: 223-232 (2003).
82. Uchaipichat, V., Mackenzie, P. I., Guo, X. H., Gardner-Stephen, D., Galetin, A., Houston, J. B. and Miners, J. O.: Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos., 32: 413-423 (2004).
83. King, C. D., Green, M. D., Rios, G. R., Coffman, B. L., Owens, I. S., Bishop, W. P. and Tephly, T. R.: The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch. Biochem. Biophys., 332: 92-100 (1996).
84. Mackenzie, P. I.: Rat liver UDP-glucuronosyltransferase. Identification of cDNAs encoding two enzymes which glucuronidate testosterone, dihydrotestosterone, and beta-estradiol. J. Biol. Chem., 262: 9744-9749 (1987).
85. Mackenzie, P. I., Mojarrabi, B., Meech, R. and Hansen, A.: Steroid UDP glucuronosyltransferases: characterization and regulation. J. Endocrinol., 150: S79-86 (1996).
86. Iwano, H., Yokota, H., Ohgiya, S., Yotumoto, N. and Yuasa, A.: A critical amino acid residue. Asp446, in UDPglucuronosyltransferase, Biochem. J., 325: 587-591 (1997).
87. Meech, R., Yogalingam, G. and Mackenzie, P. I.: Mutational analysis of the carboxy-terminal region of UDPglucuronosyltransferase 2B1. DNA Cell Biol., 15: 489-494 (1996).
88. Bosma, P. J., Seppen, J., Goldhoorn, B., Bakker, C., Oude Elferink, R. P., Roy Chowdhury, J., Roy Chowdhury, N. and Jansen, P. L.: Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J. Biol. Chem., 269: 17960-17964 (1994).
89. Watanabe, Y., Nakajima, M., Ohashi, N., Kume, T. and Yokoi, T.: Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab. Dispos., 31: 589-595 (2003).
90. Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L. and Ratain, M. J.: Genetic predisposition to the metabolism of irinotecan (CPT-11)-Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest., 101: 847-854 (1998).
91. Coffman, B. L., Rios, G. R., King, C. D. and Tephly, T. R.: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos., 25: 1-4 (1997).
92. Barbier, O., Turgeon, D., Girard, C., Green, M. D., Tephly, T. R., Hum, D. W. and Belanger, A.: 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos., 28: 497-502 (2000).
93. Bublitz, C. and Lawler, C. A.: The levels of nicotinamide nucleotides in liver microsomes and their possible significance to the function of hexose phosphate dehydrogenase. Biochem. J., 245: 263-267 (1987).
94. Piccirella, S., Czegle, I., Lizak, B., Margittai, E., Senesi, S., Papp, E., Csala, M., Fulceri, R., Csermely, P., Mandl, J., Benedetti, A. and Banhegyi, G.: Uncoupled redox systems in the lumen of the endoplasmic reticulum. Pyridine nucleotides stay reduced in an oxidative environment. J. Biol. Chem., 281: 4671-4677 (2006).
95. Quemeneur, E., Guthapfel, R. and Gueguen, P.: A major phosphoprotein of the endoplasmic reticulum is protein disulfide isomerase. J. Biol. Chem., 269: 5485-5488 (1994).
96. Wearsch, P. A. and Nicchitta, C. V.: Interaction of endoplasmic reticulum chaperone GRP94 with peptide substrates is adenine nucleotide-independent. J. Biol. Chem., 272: 5152-5156 (1997).
97. Rosser, M. F., Trotta, B. M., Marshall, M. R., Berwin, B. and Nicchitta, C. V.: Adenosine nucleotides and the regulation of GRP94-client protein interactions. Biochemistry, 43: 8835-8845 (2004).
98. Guthapfel, R., Gueguen, P. and Quemeneur, E.: ATP binding and hydrolysis by the multifunctional protein disulfide isomerase. J. Biol. Chem., 271: 2663-2666 (1996).
99. Clairmont, C. A., De Maio, A. and Hirschberg, C. B.: Translocation of ATP into the lumen of rough endoplasmic reticulumderived vesicles and its binding to luminal proteins including BiP (GRP 78) and GRP 94. J. Biol. Chem., 267: 3983-3990 (1992).
100. Agarwal, A. K., Monder, C., Eckstein, B. and White, P. C.: Cloning and expression of rat cDNA encoding corticosteroid 11beta-dehydrogenase. J. Biol. Chem., 264: 18939-18943 (1989).
101. Kornel, L. and Saito, Z.: Studies on steroid conjugates-VIII: Isolation and characterization of glucuronide-conjugated metabolites of cortisol in human urine. J. Steroid. Biochem., 6: 1267-1284 (1975).
102. Pogell, B. M. and Leloir, L. F.: Nucleotide activation of liver microsomal glucuronidation. J. Biol. Chem., 236: 293-298 (1961).
103. Zakim, D. and Vessey, D. A.: Regulation of microsomal UDPglucuronyltransferase. Mechanism of activation by UDP-Nacetylglucosamine. Biochem. Pharmacol., 26: 129-131 (1977).
104. Wilkinson, J. and Hallinan, T.: Stimulation of steroid glucuronidation by uridine diphosphate N-acetylglucosamine and by microsomal disruption. Biochem. J., 168: 125-127 (1977).
105. Hauser, S. C., Ransil, B. J., Ziurys, J. C. and Gollan, J. L.: Interaction of uridine 5′-diphosphoglucuronic acid with microsomal UDP-glucuronosyltransferase in primate liver: the facilitating role of uridine 5′-diphospho-N-acetylglucosamine. Biochim. Biophys. Acta, 967: 141-148 (1988).
106. Vanstapel, F. and Blanckaert, N.: Topology and regulation of bilirubin UDP-glucuronyltransferase in sealed native microsomes from rat liver. Arch. Biochem. Biophys., 263: 216-225 (1988).
107. Bossuyt, X. and Blanckaert, N.: Mechanism of stimulation of microsomal UDP-glucuronosyltransferase by UDP-N-acetylglucosamine. Biochem. J., 305: 321-328 (1995).
108. Bossuyt, X. and Blanckaert, N.: Uridine diphosphoxylose enhances hepatic microsomal UDP-glucuronosyltransferase activity by stimulating transport of UDP-glucuronic acid across the endoplasmic reticulum membrane. Biochem. J., 315: 189-193 (1996).
109. Harrington, W. R., Sengupta, S. and Katzenellenbogen, B. S.: Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology, 147: 3843-3850 (2006).
110. Nurrochmad, A., Ishii, Y., Nakanoh. H., Inoue, T., Horie, T., Sugihara, K., Ohta, S., Taketomi, A., Maehara, Y. and Yamada, H.: Activation of morphine glucuronidation by fatty acyl-CoAs and its plasticity: A comparative study in human and rodents including chimeric mide carrying human liver. Drug Metab. Pharmacokinet., in press.
111. Fargeman, N. J. and Knudsen, J.: Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signalling. Biochem. J., 323: 1-12 (1997).
112. Coleman, R. A., Lewin, T. M. and Muoio, D. M.: Physiological and nutritional regulation of enzymes of triacylglycerol synthesis. Annu. Rev. Nutr., 20: 77-103 (2000).
113. Glatz, J. F. C, van der Vusse, G. J. and Veerkamp, J. H.: Fatty acid-binding proteins and their physiological significance. News Physiol. Sci., 3: 41-44 (1988).
114. Rasmussen, J. T., Borchers, T. and Knudsen, J.: Comparison of the binding affinities of acyl-CoA-binding protein and fattyacid-binding protein for long-chain acyl-CoA esters. Biochem. J., 265: 849-855 (1990).
115. Sterchele, P. F., Vanden Heuvel, J. P., Davis, J. W., Shrago, E., Knudsen, J. and Peterson, R. E.: Induction of hepatic acyl-CoAbinding protein and liver fatty acid-binding protein by perfluorodecanoic acid in rats. Lack of correlation with hepatic long-chain acyl-CoA levels. Biochem. Pharmacol., 48: 955-966 (1994).
116. Knudsen, J., Jensen, M. V., Hansen, J. K., Fargeman, N. J., Neergaard, T. B. F. and Gaigg, B.: Role of acylCoA binding protein in acylCoA transport, metabolism and cell signaling. Mol. Cell. Biochem., 192: 95-103 (1999).
117. Hertz, R., Magenheim, J., Berman, I. and Bar-Tana, J.: Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4a. Nature, (Lond.) 392: 512-516 (1998).
118. Osabe, M., Sugatani, J., Fukuyama, T., Ikushiro, S., Ikari, A. and Miwa, M.: Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferators-activated receptor a in male rats fed a high-fat and high-sucrose diet. Drug Metab. Dispos., 36: 294-302 (2008).
119. Brecher, P.: The interaction of long-chain acyl CoA with membranes. Mol. Cell. Biochem., 57: 3-15 (1983).
120. Constantinides, P. P. and Steim, J. M.: Physical properties of fatty acyl-CoA. Critical micelle concentrations and micellar size and shape. J. Biol. Chem., 260: 7573-7580 (1985).
121. Tsoutsikos, P., Miners, J. O., Stapleton, A., Thomas, A., Sallustio, B. C. and Knights, K. M.: Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem. Pharmacol., 67: 191-199 (2004).
122. Rowland, A., Knights, K. M., Mackenzie, P. I. and Miners, J. O.: The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab. Dispos., 36: 1056-1062 (2008).
123. Burchell, B. and Coughtrie, M. W.: UDP-glucuronosyltransferases. Pharmacol. Ther., 43: 261-289 (1989).
124. Senay, C., Jedlitschky, G., Terrier, N., Burchell, B., Magdalou, J. and Fournel-Gigleux, S.: The importance of cysteine 126 in the human liver UDP-glucuronosyltransferase UGT1A6. Biochim. Biophys. Acta, 1597: 90-96 (2002).
125. Ikushiro, S., Emi, Y. and Iyanagi, T.: Activation of glucuronidation through reduction of a disulfide bond in rat UDPglucuronosyltransferase 1A6. Biochemistry, 41: 12813-12820 (2002).
126. Ghosh, S. S., Lu, Y., Lee, S. W., Wang, X., Guha, C., Roy-Chowdhury, J. and Roy-Chowdhury, N.: Role of cysteine residues in the function of human UDP-glucuronosyltransferase isoform 1A1 (UGT1A1). Biochem. J., 392: 685-692 (2005).
127. Horie, S., Isobe, M. and Suga, T.: Changes in CoA pools in hepatic peroxisomes of the rat under various conditions. J. Biochem., 99: 1345-1352 (1986).
128. Tubbs, P. K. and Garland, P. B.: Variations in tissue contents of coenzyme A thio esters and possible metabolic implications. Biochem. J., 93: 550-557 (1964).
129. Bakke, O. M. and Berge, R. K.: Lipid-metabolizing enzymes, CoASH and long-chain acyl-CoA in rat liver after treatment with tiadenol, nicotinic acid and niadenate. Biochem. Pharmacol., 31: 3930-3933 (1982).
130. World Health Organization: Cancer pain relief with a guide to opioid availability (2nd Ed.). Geneva, Switzerland, WHO, 1986.
131. Fujimoto, J. M. and Way, E. L.: Isolation and crystallization of bound morphine from urine of human addicts. J. Pharmacol. Exp. Ther., 121: 340-346 (1957).
132. Yoshimura, H., Oguri, K. and Tsukamoto, H.: Metabolism of drugs. LXII. Isolation and identification of morphine glucuronides in urine and bile of rabbits. Biochem. Pharmacol., 18: 279-286 (1969).
133. Oguri, K., Ida, S., Yoshimura, H. and Tsukamoto, H.: Metabolism of drugs. LXIX. Studies on the urinary metabolites of morphine in several mammalian species. Chem. Pharm. Bull. (Tokyo), 18: 2414-2419 (1970).
134. Kuo, C. K., Hanioka, N., Hoshikawa, Y., Oguri, K. and Yoshimura, H.: Species difference of site-selective glucuronidation of morphine. J. Pharmacobio-dyn., 14: 187-193 (1991).
135. Osborne, R., Joel, S., Trew, D. and Slevin, M.: Analgesic activity of morphine-6-glucuronide. Lancet, i: 828 (1988).
136. Hanna, M. H., Peat, S. J., Woodham, M., Knibb, A. and Fung, C.: Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br. J. Anaesth., 64: 547-550 (1990).
137. Osborne, R., Thompson, P., Joel, S., Trew, D., Patel, N. and Slevin, M.: The analgesic activity of morphine-6-glucuronide. Br. J. Clin. Pharmacol., 34: 130-138 (1992).
138. Portenoy, R. K., Thaler, H. T., Inturrisi, C. E., Friedlander-Klar, H. and Foley, K. M.: The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin. Pharmacol. Ther., 51: 422-431 (1992).
139. Faura, C. C., Moore, R. A., Horga, J. F., Hand, C. W. and McQuay, H. J.: Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J. Pain Symptom Manage., 11: 95-102 (1996).
140. Tighe, K. E., Webb, A. M. and Hobbs, G. J.: Persistently high plasma morphine-6-glucuronide levels despite decreased hourly patient-controlled analgesia morphine use after single-dose diclofenac: potential for opioid-related toxicity. Anesth. Analg., 88: 1136-1142 (1999).
141. Penson, R. T., Joel, S. P., Bakhshi, K., Clark, S. J., Langford, R. M. and Slevin, M. L.: Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin. Pharmacol. Ther., 68: 667-676 (2000).
142. Klepstad, P., Kaasa, S. and Borchgrevink, P. C.: Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur. J. Clin. Pharmacol., 55: 713-719 (2000).
143. Loä tsch, J. and Geisslinger, G.: Current evidence for a genetic modulation of the response to analgesics. Pain, 121: 1-5 (2006).
144. Hirota, T., Ieiri, I., Takane, H., Sano, H., Kawamoto, K., Aono, H., Yamasaki, A., Takeuchi, H., Masada, M., Shimizu, E., Higuchi, S. and Otsubo, K.: Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab. Dispos., 31: 677-680 (2003).
145. Klepstad, P., Rakvåg, T. T., Kaasa, S., Holthe, M., Dale, O., Borchgrevink, P. C., Baar, C., Vikan, T., Krokan, H. E. and Skorpen, F.: The 118A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand., 48: 1232-1239 (2004).
146. Campa, D., Gioia, A., Tomei, A., Poli, P. and Barale, R.: Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther., 83: 559-566 (2008).
147. Duguay, Y., Baá aá r, C., Skorpen, F. and Guillemette, C.: A novel functional polymorphism in the uridine diphosphateglucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther., 75: 223-233 (2004).